背景:肿瘤浸润淋巴细胞(TIL)是响应癌症的重要免疫成分。乳腺癌组织中TIL含量较高的患者,包括T细胞毒性和T辅助细胞以及B和罕见的自然杀伤(NK)细胞,有更有利的临床结果。
目的:分析伊拉克女性乳腺肿瘤组织(浸润性和良性)中CD20-B细胞和CD56-NK细胞表面生物标志物蛋白的表达率,并探讨其与浸润性乳腺癌组织分级的关系。
方法:这项回顾性研究纳入了一百零75个存档的乳腺组织:100个来自浸润性乳腺癌(BC)女性患者的存档乳腺[20个高分化BC组织;48个中分化BC和32个低分化BC组织];50个来自良性乳腺肿瘤的女性患者和25个明显正常的健康乳腺组织的组织活检(包括作为本研究的对照组)。通过利用免疫酶抗原检测系统,通过使用针对这些蛋白质的特异性一级抗体,实现了免疫组织化学,以检测与存在于乳腺组织中的浸润性淋巴细胞亚群上的B细胞CD20和NK细胞CD56相关的表达的表面生物标志物蛋白质。
结果:在100个(53.0%)BC组织中的53个中观察到表达的B细胞CD20-细胞表面(CD)生物标志物蛋白的IHC反应检测,在50个(48.0%)良性乳腺肿瘤组织中,有24个,而在对照组的正常乳腺组织中检测到CD20阳性细胞表面标志物的百分比为32.0%(25个组织中有8个)。两组乳腺良恶性肿瘤与对照组比较差异均有统计学意义(P<0.05)。然而,在乳腺恶性肿瘤和良性肿瘤组之间,差异无统计学意义(p>0.05)。检测到的CD56-IHC反应显示在14%(14出100个BC组织),16%(50个良性乳腺组织中的8个)和对照乳腺组织均未显示CD56-IHC反应。在所有登记的群体中,差异无统计学意义(P>0.05)。
结论:与对照组相比,观察到的乳腺恶性肿瘤和良性肿瘤的两个研究组之间的显着差异表明,CD20阳性浸润性B细胞淋巴细胞亚群可能有助于防御良性和恶性乳腺肿瘤的这些亚群。然而,观察到的淋巴细胞亚群上存在的NK细胞CD56浸润被检查的恶性和良性乳腺肿瘤组织的比率似乎在防御这些被研究的乳腺肿瘤组中发挥无关的作用。
BACKGROUND: Tumor-infiltrating lymphocytes (TIL) are important immunological components in response to cancers. Patients with higher numbers of TIL in breast cancerous tissues, comprising T- cytotoxic and T - helper cells along with B- and rare natural killer (NK) cells, have more favorable clinical outcomes.
OBJECTIVE: To analyze the rate of the expressed surface biomarker proteins of CD20-B cells and CD56- NK cells on the infiltrative lymphocytic subpopulations in a group of breast tumorous tissues (invasive and benign) from female patients in Iraq and explore the relations to the grade of the invasive breast cancerous tissues.
METHODS: One hundred and 75 archived breast tissues were enrolled in this retrospective research: 100 archived breast from female patients with invasive breast cancers (BC) [20 well differentiated BC tissues; 48 moderately differentiated BC and 32 poorly differentiated BC tissues]; 50 tissue biopsies from female patients with benign breast tumors and 25 apparently normal individuals with healthy breast tissues (included as the control group for this study). Immunohistochemistry was achieved for the detection of the expressed surface biomarker proteins related to B cell CD20 and NK cell CD56 present on the infiltrative lymphocytic subpopulations in breast tissues by using specific primary antibodies for these proteins via utilizing an immune-enzymatic antigen detection system.
RESULTS: The detection of IHC reactions for the expressed B cell CD20 - cell surface ( CD) biomarker proteins were observed in 53 out of 100 (53.0%) BC tissues, and in 24 out of 50 (48.0%) benign breast tumorous tissues, while CD20- positive cell surface markers was detected in apparently healthy breast tissues of the control group in a percentage of 32.0% (8 out of 25 tissues). Statistical significant differences (P<0.05) between both groups of malignant and benign breast tumors and the control group were found. However, between breast malignant and benign tumor groups, no significant difference was found ( p >0.05). Detection of CD56- IHC reactions revealed in 14% (14 out of 100 BC tissues), in 16% (8 out of 50 benign breast tissues) and none of control breast tissues revealed CD56- IHC reactions. Among all the enrolled groups, no significant differences (P>0.05) were detected.
CONCLUSIONS: The observed significant rates that showed highly significant differences between both studied groups of breast malignant and benign tumor in comparison to the control group indicate that the CD20- positive infiltrative B cell- lymphocytic subpopulations might contributed in the defense against these subsets of benign and malignant breast tumors. However, the observed rates of NK cell CD56 present on the lymphocytic subpopulations infiltrating the examined malignant and benign breast tumorous tissues seeming to play irrelevant roles in the defense against these studied breast tumor groups.